← Back to Search

Other

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression (CHERRY Trial)

N/A
Waitlist Available
Led By Lyndon Jones, PhD, FCOptom
Research Sponsored by SightGlass Vision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial studied the choroid, a layer of tissue in the eye, & its role in near-sightedness.

Who is the study for?
This trial is for individuals already enrolled in the CPRO-1802-001 study who have near-sightedness, including degenerative or progressive myopia. Participants must be minors who've given their assent and whose parents or guardians have signed a consent letter. Those with temporary health issues affecting the eyes like colds, allergies, or fatigue cannot join.
What is being tested?
The study is testing a new type of spectacle lens designed to control the progression of myopia by examining changes in choroidal thickness (a layer at the back of the eye) throughout the day.
What are the potential side effects?
Since this trial involves wearing special glasses, side effects may include discomfort from wearing new lenses, potential headaches or eye strain during adaptation to lenses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Choroidal thickness
Secondary study objectives
Visual field

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Subjects wearing novel spectacle lenses will be assessed
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Novel spectacle lens design
2022
N/A
~60

Find a Location

Who is running the clinical trial?

SightGlass Vision, Inc.Lead Sponsor
10 Previous Clinical Trials
1,083 Total Patients Enrolled
University of WaterlooOTHER
127 Previous Clinical Trials
214,822 Total Patients Enrolled
Lyndon Jones, PhD, FCOptomPrincipal InvestigatorCentre for Ocular Research & Education, Canada
12 Previous Clinical Trials
456 Total Patients Enrolled
Jill Woods, BSc, MCOptomStudy DirectorCentre for Ocular Research & Education, Canada
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top